GlassScriptPhysician profile
Preethi Ramachandran
NPI 1366828899
$9,550.89
in general payments reported to CMS, 2019-2025
44 companies · $2,570 in 2025
The $2,570 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $90.98 · 2021: $1,421 · 2022: $929 · 2023: $1,282 · 2024: $2,910 · 2025: $2,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,560 · Consulting Fee: $2,750 · Honoraria: $200 · Long Term Medical Supply Or Device Loan: $183 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,559.57 |
| Consulting Fee | $2,750.00 |
| Honoraria | $200.00 |
| Long Term Medical Supply Or Device Loan | $183.03 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $1,486.05 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $1,153.77 | 2019-2025 | |
| Incyte Corporation | $1,070.11 | 2024-2025 | Monjuvi, Jakafi, Niktimvo |
| Astrazeneca Pharmaceuticals LP | $959.53 | 2020-2025 | Calquence, Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $507.24 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $410.06 | 2019-2025 | |
| Janssen Biotech, INC. | $356.62 | 2021-2025 | Tecvayli, Rybrevant, Erleada |
| E.R. Squibb & Sons, L.L.C. | $330.42 | 2019-2025 | Opdivo, Krazati, Augtyro |
| Daiichi Sankyo INC. | $241.93 | 2021-2024 | Enhertu |
| Lilly USA, LLC | $221.29 | 2022-2025 | Verzenio, Jaypirca |
| Seagen INC. | $218.61 | 2021-2022 | |
| Foundation Medicine, INC. | $202.16 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $183.00 | 2021-2025 | Libtayo, Lynozyfic |
| Glaxosmithkline, LLC. | $179.76 | 2021-2025 | Ojjaara |
| Array Biopharma INC | $155.92 | 2021-2025 | Lorbrena, Braftovi, Xalkori |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $154.55 | 2019-2025 | Reblozyl, Opdivo, Opdualag |
| Aveo Pharmaceuticals, INC. | $153.55 | 2024-2025 | |
| Genzyme Corporation | $136.61 | 2021-2025 | |
| Gilead Sciences, INC. | $128.52 | 2021-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $116.17 | 2024-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Stemline Therapeutics INC. | $111.28 | 2024-2025 | Orserdu |
| Genentech USA, INC. | $110.12 | 2020-2025 | Phesgo, Kadcyla, Perjeta |
| Eisai INC. | $96.21 | 2021-2025 | |
| Abbvie INC. | $95.31 | 2021-2025 | |
| Exelixis INC. | $93.94 | 2023 | Cabometyx |
| Astellas Pharma US INC | $93.84 | 2019-2025 | Padcev, Vyloy |
| Acrotech Biopharma INC. | $79.66 | 2021-2022 | |
| Tempus Ai, INC | $71.29 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $60.47 | 2021-2024 | Tazverik, Onivyde, Somatuline Depot |
| Epizyme, INC. | $53.05 | 2021 | |
| Puma Biotechnology, INC. | $37.45 | 2022-2024 | |
| Sirtex Medical INC | $33.05 | 2024 | Sir-Spheres Microspheres |
| Legend Biotech USA INC. | $31.03 | 2025 | Carvykti |
| Alexion Pharmaceuticals, INC. | $30.07 | 2025 | Ultomiris |
| Caris Mpi, INC. | $29.82 | 2025 | Mi Cancer Seek |
| Pharmacosmos Therapeutics INC. | $24.02 | 2024 | Cosela |
| Sobi, INC | $19.97 | 2025 | |
| Agios Pharmaceuticals, INC. | $19.45 | 2025 | Pyrukynd |
| Kyowa Kirin, INC. | $18.46 | 2022 | |
| Amgen INC. | $17.67 | 2020 | |
| Kite Pharma, INC. | $16.51 | 2021 | |
| Rigel Pharmaceuticals, INC. | $15.91 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.48 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preethi Ramachandran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.